Rare Disease Patients

group

Last mentioned: Feb 24, 2026

Timeline

  1. Expected Finalization

    Anticipated period for final guidance after public comment and review.

  2. New System Proposed

    FDA formally announces the proposed framework for customized drug approvals.

  3. START Program

    CBER launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.

  4. ASO Guidance

    FDA issues initial draft guidance for ASO products for ultra-rare diseases.

Stories mentioning Rare Disease Patients 1

regulation Bullish

FDA Proposes Streamlined Framework for N-of-1 and Rare Disease Therapies

The FDA has unveiled a proposed regulatory pathway designed to accelerate the approval of customized, patient-specific therapies for ultra-rare diseases. This initiative aims to shift from traditional population-based clinical trials to a data-driven model that supports individualized genomic medicine.

2 sources